Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
17.73
-0.07 (-0.42%)
Bozor ochiq: Aug 12, 2026, 3:58 PM EDT
17.80
0.00 (0.00%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Trevi Therapeutics, Inc. klinik bosqichdagi biofarmatsevtika kompaniyasi bo'lib, idiomatik o'pka fibroziga (IPF) va IPF bo'lmagan interstitsial o'pka kasalliklari, shuningdek, refrakter surunkali yo'tal bilan og'rigan bemorlarda surunkali yo'talni davolash uchun tadqiqot terapiyasini ishlab chiqadi va tijoratlashtiradi. Kompaniya IPF bilan og'rigan bemorlarda surunkali yo'talni davolash uchun IPF bilan nalbuphin ERda yo'talni kamaytirish bo'yicha 2b bosqichli klinik sinovda va refrakter surunkali yo'tal bilan og'rigan bemorlarda 2a bosqichli klinik sinovda bo'lgan nalbuphinning og'iz orqali chiqariladigan uzaytirilgan shakli bo'lgan Haduvio'ni ishlab chiqadi. Trevi Therapeutics, Inc. turli xil formulalarda nalbuphin gidroxloridini o'z ichiga olgan mahsulotlarni ishlab chiqish va tijoratlashtirish uchun Keenova Therapeutics plc bilan litsenzion kelishuvga ega. Trevi Therapeutics, Inc. 2011 yilda tashkil etilgan va shtab-kvartirasi Nyu-Xeyven, Konnektikutda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. James V. Cassella Ph.D. | Chief Development Officer |
| Dr. Thomas R. Sciascia M.D. | Co-Founder & Chief Scientific Officer |
| Katie McManus | Communications Manager |
| Mr. Christopher Galletta | Controller & Chief Accounting Officer |
| Mr. David C. Hastings CPA | Chief Financial Officer & Principal Financial Officer |
| Mr. Farrell Simon Pharm.D. | Chief Commercial Officer |
| Ms. Jennifer L. Good | Co-Founder, CEO, President, & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-06 | 10-Q | trvi-20260630.htm |
| 2026-06-04 | 8-K | trvi-20260603.htm |
| 2026-05-05 | 8-K | trvi-20260505.htm |
| 2026-05-05 | 10-Q | trvi-20260331.htm |
| 2026-04-21 | DEF 14A | trvi-20260421.htm |
| 2026-04-21 | ARS | trvi-ars-2025.pdf |
| 2026-04-17 | 8-K | d587027d8k.htm |
| 2026-04-10 | PRE 14A | trvi-20260410.htm |
| 2026-03-17 | 8-K | trvi-20260317.htm |
| 2026-03-17 | 10-K | trvi-20251231.htm |